CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 25, 2013-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will host its annual Research and Development Day on Thursday, July 11, 2013 from 12:30 – 3:30 pm at the Harvard Club in NY, NY.

The company will discuss recent advances and clinical plans for their programs targeting cancer stem cells through inhibition of the Focal Adhesion Kinase (FAK) and PI3K/mTOR signaling pathways. Lunch will be served. Please RSVP to bsullivan@verastem.com.

Guest speakers scheduled to present include:

Robert Weinberg, Ph.D.
Founding Member, Whitehead Institute
Verastem scientific co-founder and chair of the scientific advisory board
Recent advances in the understanding of cancer stem cells

José Baselga, M.D., Ph.D.
Physician in Chief, Memorial Sloan-Kettering Cancer Center
Verastem scientific advisory board member
Therapeutic targeting of mTOR and PI3-kinase in cancer

Richard Gralla, M.D.
Albert Einstein College of Medicine
President, New York Lung Cancer Alliance
Measuring clinical progress in the treatment of mesothelioma

Date: July 11, 2013
Time: 12:30pm to 3:30pm
Place: Harvard Club, 35 West 44^th Street, New York, NY
RSVP: bsullivan@verastem.com
Conference Call Dial-in: 866-515-2907
Conference Call Passcode: 60920106
Webcast: http://phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-EventDetails&EventId=4979610
Replay Dial-in: 888-286-8010
Replay Passcode: 19270318

A live, listen-only conference call of the event can be accessed by dialing 866-515-2907 five minutes prior to the start of the event and providing the passcode 60920106. A replay of the webcast will be archived on the Verastem website following the presentation date.

About Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Source: Verastem, Inc.

Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com